GRANT Guide

Home » Grants » 2022 SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship (worldwide)

This opportunity is currently closed.

Sign up for Content Alerts to stay informed when this or related funding opportunities are posted.

2022 SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship (worldwide)

The 2022 SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship from the Society for Immunotherapy of Cancer (SITC) with funding from Mallinckrodt Pharmaceuticals, supports a postdoctoral researcher, resident, research scientist, or comparable position, working on adverse events in cancer immunotherapy. Applicants must be a member of the SITC and hold an MD or MD/PhD degree. Applications are open to candidates worldwide. The fellowship provides funding of 40,000 USD over 1 year plus financial support to attend SITC´s 37th Annual Meeting. Applications close on April 5, 2022.

Create or sign in to your free account for more functionalities, including a full display of the eligibility criteria such as location and citizenship requirements.